Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radotinib - Il-Yang

Drug Profile

Radotinib - Il-Yang

Alternative Names: IY-5511; IY5511HCl; Radotinib hydrochloride; Supect

Latest Information Update: 03 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Il-Yang
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia

Most Recent Events

  • 01 Dec 2018 Final 48-month efficacy and adverse events data from the phase III RERISE trial in Chronic myeloid leukaemia presented at the 60th Annual Meeting and Exposition of the American Society of Haematology (ASH-2018)
  • 31 Oct 2018 Il-Yang plans the phase III RERISE China trial for Chronic myeloid leukaemia (Newly diagnosed) in China (PO), in December 2018 (PO) (NCT03722420)
  • 13 Jul 2018 Il-Yang completes a phase I/II trial for Chronic myeloid leukaemia (Second-line therapy or greater) in India, South Korea, and Thailand (PO) (NCT01602952)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top